PMID: 7539853Jul 1, 1995Paper

Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study

The Journal of Urology
A FawzyN Dias

Abstract

A 16-week, double-blind, placebo controlled, dose titration study was done on 100 normotensive patients age 45 years or older to determine the efficacy and safety of doxazosin, a selective alpha 1-adrenoceptor antagonist, in the treatment of benign prostatic hyperplasia (BPH). Of the 41 efficacy evaluable patients 88% underwent dose titration to a maximum of 8 mg. doxazosin once daily. Maximum and average urinary flow rates increased significantly above baseline with doxazosin (2.9 ml. per second and 1.4 ml. per second, respectively) compared with placebo (0.7 ml. per second and 0.3 ml. per second, respectively). A significant effect on maximum flow rate was noted as early as week 2 of double-blind treatment at the initial efficacy evaluation. Doxazosin was superior to placebo in patient and investigator assessments of total, obstructive and irritative BPH symptoms. The onset of efficacy for total patient-assessed symptoms was significant for doxazosin compared to placebo 4 weeks after the start of the treatment regimen. Statistically significant decreases in mean blood pressure of 4 to 6 mm. Hg were noted with doxazosin compared with placebo. Adverse events, primarily mild to moderate in severity, were reported in 44% of patie...Continue Reading

References

Aug 1, 1987·British Journal of Urology·R S KirbyE J Milroy
Jan 1, 1986·British Journal of Clinical Pharmacology·V A Alabaster, M J Davey
May 29, 1987·The American Journal of Cardiology·K Hayduk
May 29, 1987·The American Journal of Cardiology·J Rosenthal
May 29, 1987·The American Journal of Cardiology·H L ElliottJ L Reid
Jan 1, 1986·British Journal of Clinical Pharmacology·D A CoxW Singleton
May 1, 1986·British Journal of Clinical Pharmacology·J VincentJ L Reid
Jan 1, 1982·Journal of Cardiovascular Pharmacology·W SingletonB N Prichard
Mar 1, 1994·Scandinavian Journal of Urology and Nephrology·J Bendix HolmeS Elkjaer Husted

❮ Previous
Next ❯

Citations

Nov 6, 2010·International Urology and Nephrology·Gokhan FaydaciMurat Tuncer
Aug 1, 2002·Current Urology Reports·Kevin T McVary
Jul 21, 2004·Current Urology Reports·Jaspreet S Sandhu, Alexis E Te
Mar 26, 2004·European Urology·Michael MarbergerJean de la Rosette
Dec 26, 2001·Urology·B Akduman, E D Crawford
Jan 18, 2002·Urology·John W KusekUNKNOWN MTOPS Research Group
Jan 28, 1998·Clinical Therapeutics·R Guthrie
Feb 14, 2002·Australian Family Physician
Nov 16, 2012·Journal of Human Genetics·Ryo TakataYusuke Nakamura
Feb 16, 2005·Prostate Cancer and Prostatic Diseases·W D Steers, R S Kirby
Jul 20, 2012·The New England Journal of Medicine·Aruna V Sarma, John T Wei
Aug 11, 2001·The Journal of Clinical Hypertension·N MartellUNKNOWN HT-BPH Group
Sep 1, 2006·International Journal of Clinical Practice·A C L PompeoUNKNOWN Doxazosin and Tamsulosin Study Investigator Group
Nov 24, 1998·Journal of Clinical Pharmacology·V VashiK Phillips
Dec 1, 2007·Clinical Interventions in Aging·Timothy J Wilt, Roderick MacDonald
Nov 26, 2009·Patient Preference and Adherence·Jaspreet S Sandhu
Mar 25, 2008·Therapeutics and Clinical Risk Management·Angelo J Cambio, Christopher P Evans

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.